Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Conditions
Interventions
APL-2
Locations
30
Colombia
Julian Coronel Medical Center
Cali, Colombia
Research Center of the Colombian Clinical Life Cancer Foundation
Medellín, Colombia
Queen Mary Hospital
Hong Kong, Hong Kong
Princess Margaret Hospital
Kwai Chung, Hong Kong
Prince and Wales Hospital
Shatin, Hong Kong
Hospital Ampang
Ampang, Selangor, Malaysia
Start Date
August 27, 2019
Primary Completion Date
June 23, 2021
Completion Date
June 23, 2021
Last Updated
October 21, 2022
NCT03520647
NCT04645199
NCT07152288
NCT06411626
NCT06298955
NCT05389449
Lead Sponsor
Apellis Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions